Jorge H Mukdsi1, Silvina Gutiérrez1, Belén Barrón2, Pablo Novoa2, Segundo Fernández3, Ana B de Diller1, Alicia I Torres1, Richard N Formica4, Marcelo Orías2. 1. Centro de Microscopía Electrónica, Facultad de Ciencias Médicas, Universidad Nacional de Córdoba, and Haya de la Torre esquina Enrique Barros, Ciudad Universitaria, Córdoba, Argentina. 2. Servicio de Nefrología, Sanatorio Allende, Bernardo de Irigoyen 384, Córdoba, Argentina. 3. CIPERCA Centro de diálisis, Catamarca, Argentina. 4. Department of Medicine, Section of Nephrology, Yale University School of Medicine, USA.
Abstract
BACKGROUND: Fabry disease is caused by an X-linked recessive inborn error of glycosphingolipid metabolism with deficient activity of a lysosomal enzyme, alpha-galactosidase A (α-GalA). CASE PRESENTATION: A 46 year-old man with progressive kidney disease showed on kidney biopsy electron microscopic evidence of Fabry disease. The patient had no systemic manifestations of Fabry disease, despite residual α-GalA activity, therefore genetic testing was done by direct DNA sequencing, demonstrating a new GAL A gene mutation (C174G-exon 3). After three years of enzyme replacement therapy (agalsidase beta) treatment, a second biopsy was done. Although there was demonstrable clearance of intracellular inclusions, remarkable podocyte activation was evident. CONCLUSIONS: This report represents an unusual renal variant of Fabry disease and provides histologic data on long-term follow up after enzyme replacement therapy.
BACKGROUND:Fabry disease is caused by an X-linked recessive inborn error of glycosphingolipid metabolism with deficient activity of a lysosomal enzyme, alpha-galactosidase A (α-GalA). CASE PRESENTATION: A 46 year-old man with progressive kidney disease showed on kidney biopsy electron microscopic evidence of Fabry disease. The patient had no systemic manifestations of Fabry disease, despite residual α-GalA activity, therefore genetic testing was done by direct DNA sequencing, demonstrating a new GAL A gene mutation (C174G-exon 3). After three years of enzyme replacement therapy (agalsidase beta) treatment, a second biopsy was done. Although there was demonstrable clearance of intracellular inclusions, remarkable podocyte activation was evident. CONCLUSIONS: This report represents an unusual renal variant of Fabry disease and provides histologic data on long-term follow up after enzyme replacement therapy.
Entities:
Keywords:
Enzyme replacement therapy; Fabry disease; Kidney electron microscopy
Authors: Mary H Branton; Raphael Schiffmann; Sharda G Sabnis; Gary J Murray; Jane M Quirk; Gheona Altarescu; Lev Goldfarb; Roscoe O Brady; James E Balow; Howard A Austin Iii; Jeffrey B Kopp Journal: Medicine (Baltimore) Date: 2002-03 Impact factor: 1.889
Authors: Björn Oqvist; Barry M Brenner; João Paulo Oliveira; Alberto Ortiz; Roland Schaefer; Einar Svarstad; Christoph Wanner; Kate Zhang; David G Warnock Journal: Nephrol Dial Transplant Date: 2009-03-16 Impact factor: 5.992
Authors: Dominique P Germain; Stephen Waldek; Maryam Banikazemi; David A Bushinsky; Joel Charrow; Robert J Desnick; Philip Lee; Thomas Loew; Anouk C Vedder; Rekha Abichandani; William R Wilcox; Nathalie Guffon Journal: J Am Soc Nephrol Date: 2007-04-04 Impact factor: 10.121
Authors: Beth L Thurberg; Helmut Rennke; Robert B Colvin; Steven Dikman; Ronald E Gordon; A Bernard Collins; Robert J Desnick; Michael O'Callaghan Journal: Kidney Int Date: 2002-12 Impact factor: 10.612
Authors: Diana Albay; Sharon G Adler; Jaya Philipose; C C Calescibetta; Stephen G Romansky; Arthur H Cohen Journal: Mod Pathol Date: 2005-05 Impact factor: 7.842
Authors: Alberto Ortiz; João P Oliveira; Christoph Wanner; Barry M Brenner; Stephen Waldek; David G Warnock Journal: Nat Clin Pract Nephrol Date: 2008-04-22
Authors: Susana Ferreira; Alberto Ortiz; Dominique P Germain; Miguel Viana-Baptista; António Caldeira-Gomes; Marta Camprecios; Maria Fenollar-Cortés; Ángel Gallegos-Villalobos; Diego Garcia; José Antonio García-Robles; Jesús Egido; Eduardo Gutiérrez-Rivas; José Antonio Herrero; Sebastián Mas; Raluca Oancea; Paloma Péres; Luis Manuel Salazar-Martín; Jesús Solera-Garcia; Helena Alves; Scott C Garman; João Paulo Oliveira Journal: Mol Genet Metab Date: 2014-11-09 Impact factor: 4.797
Authors: Dominique P Germain; Perry M Elliott; Bruno Falissard; Victor V Fomin; Max J Hilz; Ana Jovanovic; Ilkka Kantola; Aleš Linhart; Renzo Mignani; Mehdi Namdar; Albina Nowak; João-Paulo Oliveira; Maurizio Pieroni; Miguel Viana-Baptista; Christoph Wanner; Marco Spada Journal: Mol Genet Metab Rep Date: 2019-02-06
Authors: G Serebrinsky; M Calvo; S Fernandez; S Saito; K Ohno; E Wallace; D Warnock; H Sakuraba; J Politei Journal: Mol Genet Metab Rep Date: 2015-06-07